.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, patients with metastatic intestinal tumors that got biomarker-matched therapies based on distributing growth DNA profiling revealed a higher professional perk than those receiving unequaled treatment.